Jon D. Williams, Ph.D. Manger GlaxoSmithKline, Research Triangle Park, NC 27709

Mass spectrometry (MS) has become an essential tool for the study of biological problems.  Besides being the bedrock analytical technique for proteomics and metabolomics, it is an indispensable at GSK for recombinant protein quality control, post-translational site modification identification, biochemical assays, and protein quantitation.  This seminar will demonstrate how the GSK-RTP biological MS team has impacted drug discovery operations by creating and adopting new technologies and collaborating and engaging with other drug discovery scientists.  Featured will be highlights from non-denaturing mass spectrometry efforts, chemical proteomics, and high throughput MS screening.  The strategy and rationale for using metabolomics in drug discovery and clinical development will also be provided.